Potent induction of antitumor immunity by combining cryo-thermal ablation with immune checkpoint inhibitors in hepatocellular carcinoma.

Abstract in brief

• This study explored how combining cryothermal ablation (CryoA) with immune checkpoint inhibitors (ICIs) like PD1 and CTLA4 can enhance anti-tumor immunity in a mouse model of liver cancer (HCC), showing that this combo shifts the tumor environment to be more immune-active and prolongs survival.
• CryoA alone triggers immune responses by causing tumor cell death and activating immune cells but isn't enough by itself to significantly extend survival; when paired with ICIs, it significantly boosts the immune system's ability to attack tumors and even eliminate distant untreated tumors, demonstrating an abscopal effect.
• The combination therapy improves the tumor microenvironment by increasing cytotoxic CD8 T cells that attack cancer cells, while reducing suppressive cells like granulocytes, thus transforming "cold" tumors into "hot" ones more responsive to immunotherapy, offering a promising new approach for treating HCC.]